June 2011 in “International Journal of Dermatology” A man's red tattoo caused a skin reaction and hair loss in his beard, which improved after treatment.
Intralesional methotrexate effectively treats alopecia areata by reducing TNF-α levels, leading to hair regrowth.
16 citations
,
February 2018 in “European Journal of Endocrinology” Diagnosing hyperandrogenism in women is complex and requires accurate testing methods and consideration of SHBG levels.
55 citations
,
October 2015 in “Journal of Investigative Dermatology” Alopecia areata is linked to immune-related genes, suggesting JAK inhibitors as a potential treatment.
January 2025 in “Dermatologic Therapy” Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
1 citations
,
June 2017 in “Journal of the American Academy of Dermatology” Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
April 2016 in “Journal of Investigative Dermatology” Blocking certain proteins can significantly regrow hair in severe alopecia areata.
54 citations
,
February 2012 in “Pediatrics in Review” Pediatric systemic lupus erythematosus is a severe autoimmune disease in children requiring early diagnosis and comprehensive management.
9 citations
,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
July 2024 in “Journal of Investigative Dermatology”
82 citations
,
March 2016 in “Autoimmunity reviews” Animal models have helped understand hair loss from alopecia areata and find new treatments.
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
April 2023 in “Journal of Investigative Dermatology” CD8+ T cells attack hair follicle stem cells, causing scarring and hair loss.
5 citations
,
June 2019 in “British Journal of Dermatology” Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
December 2020 in “Rossijskij žurnal kožnyh i veneričeskih boleznej” People with severe alopecia areata often have lower vitamin D levels and may have other autoimmune or allergic conditions.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
September 2025 in “Figshare” Alopecia areata involves complex immune activity, mainly Th1, with potential benefits from broader immune treatments.
3 citations
,
May 2023 in “Journal of the American Academy of Dermatology” Certain drugs can cause hair loss, but stopping the drug usually leads to hair regrowth.
March 2026 in “SHILAP Revista de lepidopterología” Rituximab may cause skin issues, but baricitinib can help improve them.
2 citations
,
December 2024 in “PLoS ONE” Hematological ratios can effectively predict and manage alopecia areata severity.
2 citations
,
February 2025 in “Archives of Dermatological Research” Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
7 citations
,
December 2014 in “Gynecological Endocrinology” LC-MS/MS is more reliable than immunoassays for diagnosing 21-hydroxylase deficiency.
75 citations
,
October 2012 in “Journal of Investigative Dermatology” Alopecia areata can be triggered by specific immune cells without genetic or environmental factors.
Early recognition and a multidisciplinary approach are crucial for effectively managing complex autoimmune conditions like SLE with CAPS and AHA.
21 citations
,
September 1977 in “Journal of Pharmaceutical Sciences” Minoxidil levels measured in human blood.
A 9-year-old girl developed type 1 diabetes and alopecia after being treated for a rare kidney disease.
8 citations
,
January 2008 in “European Journal of Pediatrics” Children with autoimmune gastritis showed improved intestinal health over time and should be checked for other autoimmune conditions.
54 citations
,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
22 citations
,
September 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.
1 citations
,
June 2019 in “Journal of Cutaneous Immunology and Allergy” Squaric acid dibutylester can cause severe skin reactions in people with allergies.